Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Beta Bionics, Inc. common stock is reported as being beneficially owned by investment funds managed by Farallon Capital Management, L.L.C. and associated individuals. The reporting group collectively reports beneficial ownership of 595,000 Shares of common stock, representing 1.3% of the outstanding class as of June 30, 2026.
Farallon and its affiliated funds hold shared voting and dispositive power over these 595,000 Shares, with no sole voting or dispositive power reported for any of the listed entities or individuals. The Farallon funds are entitled to receive dividends and sale proceeds related to these securities.
Beta Bionics, Inc. reported strong top-line growth but continued losses for the quarter ended June 30, 2026. Net sales for the quarter were $32.0 million, up from $23.2 million a year earlier, driven by the iLet insulin delivery device and its single-use consumables. Six‑month net sales reached $59.6 million. Gross profit for the first half was $35.3 million, but higher research and development, sales and marketing, and general and administrative expenses of $85.2 million led to a six‑month net loss of $45.3 million, similar to the prior‑year period.
As of June 30, 2026, the company held $44.3 million in cash and cash equivalents and $180.8 million in short‑ and long‑term U.S. Treasury investments, with total assets of $292.4 million and stockholders’ equity of $256.4 million. Net cash used in operating activities for the first half was $38.5 million. Revenue is increasingly shifting toward the pharmacy benefit plan channel, which generated $22.3 million of six‑month sales versus $37.3 million from the durable medical equipment channel. The company continues to invest in next‑generation products, including the Mint tubeless patch pump and a bihormonal iLet system, and has begun enrolling adults with type 2 diabetes in a pivotal U.S. trial. In January 2026, the FDA issued a Warning Letter citing quality system and reporting deficiencies at the Irvine, California facility following a June 2025 inspection.
Beta Bionics, Inc. reported strong growth for the quarter ended June 30, 2026, with net sales of $32.0 million, up 38% from $23.2 million a year earlier. Durable Medical Equipment channel sales were $20.4 million, while Pharmacy Benefit Plan channel sales more than doubled to $11.6 million.
Gross margin improved to , but the company remained unprofitable, with a loss from operations of $25.6 million and a net loss of $23.4 million, both wider than in 2025. Adjusted EBITDA was negative $17.7 million. Cash, cash equivalents, and investments totaled $225.2 million as of June 30, 2026.
Management reaffirmed 2026 revenue guidance of $131–$136 million and the expected mix of new patient starts via the PBP channel, while modestly raising gross margin guidance to 58.5%–59.5%. The company also highlighted progress on its iLet pivotal trial in type 2 diabetes and commercialization plans for the Mint patch pump, both subject to future FDA clearance.
Beta Bionics, Inc. has a new significant shareholder group disclosed in a Schedule 13G filing. Divisadero Street Capital Management, LP and related entities, together with William Zolezzi, report beneficial ownership of 3,072,985 shares of common stock, representing 6.9% of the class.
Within this group, Divisadero Street Partners, L.P. and its general partner Divisadero Street Partners GP, LLC each report beneficial ownership of 2,612,985 shares, or 5.9% of the common stock. Voting and dispositive rights are reported only on a shared basis; all reporting persons list zero shares with sole voting or dispositive power.
The securities are directly owned by advisory clients of Divisadero Street Capital Management, LP, and, other than Divisadero Street Partners, L.P., no individual advisory client is stated to beneficially own more than 5% of the common stock. Each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an amended insider transaction combining option exercises and share sales. On June 26 and June 29, 2026, he exercised options for a total of 10,000 shares of common stock at a conversion price of $5.10 per share and sold 10,000 shares in open-market transactions.
The weighted average sale prices were $17.046782 on June 26 and $17.0304 on June 29, with trades executed between $17.00 and about $17.12. Following these transactions, he held 166,053 shares of common stock directly. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2025. This amendment corrects the number of shares subject to the June 26, 2026 option exercise and the number of securities beneficially owned after the transactions.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an exercise-and-sell pattern in Common Stock. He exercised stock options covering 9,878 shares at an exercise price of $5.10 per share and sold 10,000 shares in open-market transactions at weighted average prices around $17.04 on June 26, 2026 and June 29, 2026. The sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2025. Following these transactions, he directly holds 165,931 shares of Common Stock, indicating he retained a large majority of his equity position.
BBNX submitted a Form 144 notice proposing the sale of 4,896 shares of Common Stock, reported as stock options, dated 06/29/2026 and to be sold for cash. The filing lists shares outstanding of 44,561,695 as of 06/29/2026. The excerpt also records prior sales by Stephen Feider: 5,104 shares sold on 06/26/2026 for $87,006.78 and 6,676 shares sold on 06/02/2026 for $85,386.04.
BBNX notice of proposed sale: a holder submitted a Form 144 for Common stock on 06/26/2026, listing 5104 shares associated with stock options and showing prior sales of 6,676 shares on 06/02/2026 with an amount of 85,386.04.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of common stock. On June 24, 2026, he sold 1,258 shares at a weighted average price of $15.0083 per share, under a pre-arranged Rule 10b5-1 Plan adopted on May 13, 2025. Following this sale, he directly holds 129,354 shares of common stock.
Beta Bionics, Inc. director Christy Jones reported an open-market sale of 1,406 shares of Common Stock at $15.00 per share. After the transaction, she directly holds 25,994 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026, indicating it was scheduled in advance.